Navigation Links
Biosyntrx, Inc. Appoints New Board Member & New VP of Operations
Date:1/12/2012

COLORADO SPRINGS, Colo., Jan. 12, 2012 /PRNewswire/ -- Biosyntrx, Inc. CEO Ellen Troyer today announced that Akos Feher has been appointed to the Biosyntrx Board of Directors.  Mr. Feher lives in Playa Del Rey, CA and holds degrees in engineering with an MBA from the University Of Southern California Marshall School Of Business. He has been a Biosyntrx strategic planning consultant for the past two years.  Mr. Feher is an innovative, passionate and profit-driven professional with more than 12 years of experience in complex projects, brands and business infrastructure including consumer electronics, medical devices and dietary supplements.

(Logo:  http://photos.prnewswire.com/prnh/20120112/SF34130LOGO)

The Biosyntrx board also promoted David Amess from Business Development Director to Vice President of Operations.  Mr. Amess has been with Biosyntrx for more than four years.  He brings a Business Administration degree and almost 20 years of experience in banking, finance, and customer service management.  David is Six Sigma certified, with a focus on statistical methods for problem solving and business model projections.

"Biosyntrx sales and revenue increased in 2011 despite today's economy," said Ellen Troyer.  "We welcome 2012 with a revised business plan, an exciting pipeline, improved operations, an 'on fire' board and executive management team with engaged and energized employees, consultants and distributors.  Opportunities are knocking in the supplement industry and Biosyntrx maintains a global open door policy to legitimate opportunity."

Spencer Thornton, MD, the Nashville TN based Biosyntrx President says, "Akos Feher and David Ames are passionate and exceptionally talented team players who will serve our stockholders and customers well in the new positions they hold."

"The appointment of David Amess as Vice President for Operations with his Six Sigma Certification is going to be a real plus in my opinion.  Adding Akos Feher to the Board of Directors will give quality business judgment and experience," said Jerre Freeman, MD. 

"Biosyntrx has proven they have the creativity required to survive economic difficulty.  I applaud these appointments and look forward to watching them grow," said Robert Osher, MD.

About Biosyntrx:  Biosyntrx is an eye-care-specific privately held company incorporated in South Carolina with customer service offices and inside product sales located in downtown Columbia. The company's executive offices including product research and development, web site development, operations, business development, marketing and education are located in Colorado Springs, Colorado.  The primary Biosyntrx eye care-specific products are BioTears, a patented product that addresses the systemic nutrient needs of the dry eye patient. Macula Complete, a potent full-spectrum multiple designed for the diagnosed AMD, or those concerned about optimal full-body health and lack of energy; Oculair, a less potent full-body multiple and Avantrx, a meal-time portion-control product.

www.biosyntrx.com  


'/>"/>
SOURCE Biosyntrx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Quark Pharmaceuticals Appoints New Chief Medical Officer
2. West Pharmaceutical Services, Inc. Appoints New Director
3. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
4. Curemark Appoints Preeminent Pediatrics Gastroenterologist
5. CVBT Appoints Dr. Nabil Dib as Principal Investigator for Phase II Heart Trial
6. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
7. Cytopia Appoints Study Chairman for JAK2 Clinical Trial
8. Enobia Pharma Appoints Industry Veterans with Commercial and Manufacturing Expertise to Expand Senior Management Team
9. NovaRx Appoints Industry Veteran as President and COO
10. Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer
11. Logical Therapeutics Appoints Peter A. Lankau as CEO and Director
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... 2017 Nevro Corp. (NYSE: NVRO), a global medical ... treatment of chronic pain, today reported financial results for the ... 2016 Accomplishment & Highlights: Achieved ... increase of 228% as reported, over the prior year ... of 612% over the prior year International ...
(Date:2/23/2017)... Calif. , Feb. 23, 2017 ... company focused on the development and commercialization of ... pain, announced that it will release fourth quarter ... Thursday, March 2nd, 2017. AcelRx management will host ... Time (1:30 p.m. Pacific Time) on March 2 ...
(Date:2/23/2017)... , Feb 23, 2017 ... Research and Markets has announced the ... Industry Forecast to 2025" report to their offering. ... of around 1.8% over the next decade to reach approximately $12.8 billion ... estimates and forecasts for all the given segments on global as well ...
Breaking Medicine Technology:
(Date:2/23/2017)... , ... February 23, 2017 , ... ... of Justice jointly issued a letter to withdraw previous guidance issued ... their gender identity. The guidance issued in May 2016 by the Obama Administration ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... with a clinician-based audience, will be participating in Rare Disease Day events, hosted ... D.C. In addition, Rare Disease Report, a website, weekly e-newsletter and quarterly publication, ...
(Date:2/23/2017)... , ... February 23, 2017 , ... Hamlin Dental Group ... that they are sponsoring a raffle. Throughout the month of February, patients who visit ... a gift card for a dinner for two at the Cheesecake Factory. , ...
(Date:2/23/2017)... Los Angeles, California (PRWEB) , ... February 23, ... ... for Global Sports Development will host a diverse symposium on “Doping ... School of Law and Sheppard Mullin Richter & Hampton LLP. The symposium will ...
(Date:2/23/2017)... ... 23, 2017 , ... ERT, a global data and technology ... Research, a leading clinical development service provider, has selected ERT’s Trial Oversight suite ... in part to an array of circumstances including the use of multiple data ...
Breaking Medicine News(10 mins):